THE WOODLANDS, TX, UNITED STATES - Aug 7, 2014 - MolecularHealth
announces the addition of Fadi Braiteh, M.D., to its advisory
board. Dr. Braiteh is a practicing oncologist with the
Comprehensive Cancer Centers of Nevada, and a leading specialist on
gastro-intestinal, digestive system and breast cancer oncology. He
joins a board comprised of numerous nationally and
oncology and pathology experts.
After receiving his medical degree from Saint Josephs
University in Beirut, Lebanon, Dr. Braiteh completed his internal
medicine internship and residency at the Yale School of Medicine
and three fellowships at the University of Texas M.D. Anderson
Cancer Center-in medical oncology, phase I drug development and
palliative care and symptom management. He has received numerous
awards, including the 2009 Susan G. Komen Scholar-In-Training
Award, the 2007 Jesse Jones Fellowship in Cancer Education Award,
and the 2005 and 2006 ASCO Foundation Merit Awards.
We are still mired in classifying cancers by what we can see in
the optical microscope, an instrument invented 350 years ago.
Modern tools have taught us that cancers are far more complex and
diverse than they look, and in the current age of genomics, we now
know the importance of analyzing cancer cells on a molecular
level, said Dr. Braiteh. This is all the result of technological
advances by companies like MolecularHealth that allow for each
specific case and each patient to be treated individually, rather
than as member of a subcategory. Next-generation sequencing, along
with this in-depth analysis, make possible the identification of
the molecular subtype of the cancer, and the ability choose
adequate treatment and avoid unnecessary exposure to futile
Lloyd Everson, M.D., chief executive officer of MolecularHealth,
Inc. added, We are fortunate to have built an incredibly strong
advisory board that is helping to guide our company as we expand
our TreatmentMAP sales efforts and reach within the molecular
diagnostic market. Given Dr. Braitehs wealth of knowledge in
oncology and cancer genetics, I know that hell be an asset to the
board, and we look forward to working with him.
MolecularHealths TreatmentMAP was
commercially launched in April and is gaining traction with
oncology practices and hospitals throughout the U.S. and Europe.
Using a proprietary analytics engine to combine precision medicine
with advanced data analysis, the offering guides physicians to the
safest and most effective cancer treatment options for their
patients. TreatmentMAP is accessible to all patients diagnosed with
solid tumor cancer, regardless of where they live.
MolecularHealth is a leading biomedical company that is
transforming molecular data into clinically actionable information
to inform the most efficient and safest cancer treatment options
for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT)
performed at MolecularHealths CLIA-certified laboratory. In
Europe, TreatmentMAP is the first registered medical device of its
kind for personalized cancer medicine and offered through a network
of certified physicians. MolecularHealth GmbH is certified
according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of
oncologists, scientists, businesspeople, and IT experts with
long-standing expertise in their fields, works in partnership with
some of the worlds leading healthcare, information
technology and NGS companies, including the U.S. Food and Drug
Administration (FDA), University of Texas MD Anderson Cancer
Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S.,
the company is headquartered in Heidelberg, Germany, and its U.S.
headquarters, including a CLIA-certified NGS lab, is located in The
Woodlands, Texas. The company also has offices in Boston, Mass.
Please visit www.molecularhealth.com
for more information and follow on Twitter at www.twitter.com/molecularhealth.
Contact for U.S.
Associate Vice President